Northland Securities reissued their buy rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a report published on Wednesday morning. The firm currently has a $40.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. BMO Capital Markets reaffirmed a buy rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Needham & Company LLC reaffirmed a buy rating and issued a $36.00 target price (up from $34.00) on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Janney Montgomery Scott reaffirmed a buy rating and issued a $35.00 target price (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Royal Bank Of Canada reaffirmed a buy rating and issued a $44.00 target price on shares of Flexion Therapeutics in a research note on Friday, July 7th. Finally, Cantor Fitzgerald set a $40.00 target price on shares of Flexion Therapeutics and gave the stock a buy rating in a research note on Monday, June 12th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $33.56.

Shares of Flexion Therapeutics (NASDAQ FLXN) opened at 29.93 on Wednesday. The stock’s market capitalization is $954.92 million. The stock has a 50 day moving average price of $24.68 and a 200-day moving average price of $22.57. Flexion Therapeutics has a 52-week low of $15.93 and a 52-week high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities research analysts predict that Flexion Therapeutics will post ($3.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Northland Securities Reaffirms “Buy” Rating for Flexion Therapeutics, Inc. (FLXN)” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.watchlistnews.com/northland-securities-reaffirms-buy-rating-for-flexion-therapeutics-inc-flxn/1616559.html.

In related news, insider Yamo Deniz acquired 1,375 shares of the stock in a transaction dated Thursday, August 31st. The stock was bought at an average cost of $25.40 per share, with a total value of $34,925.00. Following the purchase, the insider now directly owns 5,000 shares of the company’s stock, valued at $127,000. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought a total of 5,375 shares of company stock valued at $131,575 over the last three months. Corporate insiders own 15.98% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. grew its stake in shares of Flexion Therapeutics by 0.6% during the 2nd quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 338 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Flexion Therapeutics by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock valued at $2,047,000 after buying an additional 513 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Flexion Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after buying an additional 811 shares during the period. ProShare Advisors LLC grew its stake in shares of Flexion Therapeutics by 5.5% during the 2nd quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock valued at $379,000 after buying an additional 982 shares during the period. Finally, IFP Advisors Inc grew its stake in shares of Flexion Therapeutics by 24.5% during the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,000 shares during the period. 83.26% of the stock is owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.